Antiviral Drugs - Brunei Darussalam

Brunei Darussalam

The revenue in the Antiviral Drugs market of Brunei Darussalam is projected to reach US$1.44m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2028) of -0.52%, resulting in a market volume of US$1.41m by 2028.
In global comparison, United States will generate the most revenue with US$32,110.00m in 2024.
Brunei Darussalam is witnessing a growing demand for antiviral drugs due to increased awareness and proactive measures against viral infections.

Key regions: France, Brazil, South Korea, India, China

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for antiviral drugs in Brunei Darussalam has been increasing in recent years due to several factors.

Customer preferences: Customers in Brunei Darussalam are becoming more aware of the benefits of antiviral drugs in preventing and treating viral infections. The COVID-19 pandemic has also raised awareness about the importance of antiviral drugs in controlling the spread of infectious diseases.

Trends in the market: The antiviral drugs market in Brunei Darussalam has been growing steadily in recent years, driven by the increasing prevalence of viral infections and the growing demand for preventive healthcare. The market is dominated by a few major players who offer a wide range of antiviral drugs for different types of viral infections.

Local special circumstances: Brunei Darussalam has a small population and a well-developed healthcare system, which makes it easier for customers to access antiviral drugs. The government has also been actively promoting preventive healthcare and has implemented several initiatives to improve public health.

Underlying macroeconomic factors: The growing demand for antiviral drugs in Brunei Darussalam is driven by several macroeconomic factors, including the increasing prevalence of viral infections, the growing awareness about the benefits of preventive healthcare, and the government's focus on improving public health. The country's stable economy and high standard of living also make it easier for customers to afford antiviral drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.